AI
SRNE

ArchPoint Investors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

ArchPoint Investors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,500
Closed -$8K – 149
2016
Q2 		$8K Hold
1,500
– – ﹤0.01% 136
2016
Q1 		$8K Hold
1,500
– – ﹤0.01% 131
2015
Q4 		$13K Buy
+1,500
New +$12.7K 0.01% 128

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ArchPoint Investors's SRNE Position: Q3 2016 in Review

ArchPoint Investors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2016, closing a stake of 1,500 shares — an estimated $8K sold.

ArchPoint Investors first reported a position in SRNE in Q4 2015 and held it in 3 quarters. The position peaked at $13K in Q4 2015. 62 funds tracked by Wall St. Rank hold SRNE as of Q3 2016.

  • ArchPoint Investors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • ArchPoint Investors sold 1,500 Sorrento Therapeutics, Inc. shares in Q3 2016, an estimated $8K.
  • ArchPoint Investors first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • ArchPoint Investors's Sorrento Therapeutics, Inc. position peaked at $13K in Q4 2015.
  • 62 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2016.

Based on ArchPoint Investors's 13F filing for Q3 2016, filed 9 Nov 2016.